Sotorasib(Lumakras)

Sotorasib is a prescription drug targeting the KRAS G12C mutant protein. It was granted accelerated approval by the U.S. FDA on May 28, 2021, and patients should use it strictly in accordance with medical advice.

Target

KRAS G12C mutant protein (GTPase domain)

Mechanism of Action

Tumors harboring the KRAS G12C mutation (a specific mutation of the KRAS gene) are persistently in an "on" state, leading to uncontrolled and continuous cell growth. Sotorasib targets the KRAS G12C mutation and locks it in an "off" state, which may help inhibit the growth of tumor cells.

Dosage and Administration

Route and frequency of administration for Sotorasib: Oral, once daily.

The dosage of Sotorasib should be adjusted according to the patient’s actual condition. For specific details, consult a physician and strictly follow medical advice.

Recommended reading: Dosage and Administration of Sotorasib

Adverse Reactions

Common adverse reactions: Diarrhea, musculoskeletal pain, nausea, etc.

Serious adverse reactions: Hepatic disorders, pulmonary or respiratory disorders.

Reference article: Adverse Reactions of Sotorasib

Use in Special Populations

Pregnancy: It is currently unknown whether Sotorasib may cause harm to the fetus.

Lactation: It is currently unknown whether Sotorasib is excreted in human milk. Breastfeeding is not recommended during treatment and for 1 week after the last dose.

Precautions

1. Patients should be advised to immediately contact their healthcare professional if they experience signs or symptoms of abnormal liver function.

2. Patients should be advised to immediately contact and report to their healthcare professional if they develop new or worsening respiratory symptoms.

3. Patients receiving Sotorasib in combination with Panitumumab should be informed: The first dose of Sotorasib should be administered prior to the first Panitumumab infusion. In addition, Panitumumab should be withheld or discontinued whenever Sotorasib is withheld or discontinued.

from FDA，2023.04